Biogen has added two members to the executive management team of Bioverativ Inc., Biogen’s planned spin-off focused on the discovery, research, development and commercialization of treatments for hemophilia and other blood disorders. Rogerio Vivaldi, M.D., will serve as executive vice president and chief global therapeutic operations officer, and John T. Greene will serve as executive vice president and chief financial officer. The spin-off is scheduled to be completed in early 2017. “Biogen is...